Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials.
Francisco Cezar Aquino de MoraesEric PasqualottoMatheus Pedrotti ChavezRafael Oliva Morgado FerreiraTiago Biachi de CastriaRommel Mario Rodríguez BurbanoPublished in: BMC cancer (2024)
In this comprehensive systematic review and meta-analysis of RCTs, the incorporation of Zolbetuximab alongside chemotherapy offers a promising prospect for reshaping the established treatment paradigms for patients diagnosed with advanced CLDN18.2-positive GC/GEJ cancer.
Keyphrases
- systematic review
- locally advanced
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- squamous cell carcinoma
- papillary thyroid
- meta analyses
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- radiation therapy
- patient reported outcomes
- young adults
- childhood cancer
- simultaneous determination
- gas chromatography